John Aspegrén

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

Karim Fizazi, Christophe Massard, Petri Bono et al. · The Lancet Oncology · 2014 · 191 citations · Full text

Open-label Phase 1, Urology, Medicine +5

Evaluation of the clinical efficacy and safety of dexmedetomidine or medetomidine in cats and their reversal with atipamezole

Mikael Granholm, B.C. McKusick, F. C. Westerholm et al. · Veterinary Anaesthesia and Analgesia · 2006 · 165 citations

Medicine, Veterinary Science, Small Animal Internal Medicine +6

Evaluation of the clinical efficacy and safety of intramuscular and intravenous doses of dexmedetomidine and medetomidine in dogs and their reversal with atipamezole

Mikael Granholm, B.C. McKusick, F. C. Westerholm et al. · Veterinary Record · 2007 · 112 citations

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

Malaka Ameratunga, Irene Braña, Petri Bono et al. · British Journal of Cancer · 2020 · 86 citations · Full text

Clinical evaluation of the efficacy and safety of a constant rate infusion of dexmedetomidine for postoperative pain management in dogs

Chiara Valtolina, Joris H. Robben, Joost J Uilenreef et al. · Veterinary Anaesthesia and Analgesia · 2009 · 73 citations

Health Sciences, Pain Medicine, Postoperative Pain Management +12